Did you know?

While diet and exercise are the preferred choice to maintain a healthy body weight, many people require medical options to reduce their weight to a healthy level and to maintain weight loss.

Our Approach

Metabolic diseases are extremely complex, with a number of biological and environmental factors at play.

There currently are no approved medical therapies that fully address the biological mechanisms of obesity or the underlying metabolic diseases that can lead to type 2 diabetes or obesity, and many patients are still beyond reach of meaningful treatment.

ZGN-1061 is being studied as a first-in-class therapy that demonstrates a unique mechanism of action through methionine aminopeptidase 2 (MetAP2) inhibition. MetAP2 inhibitors work by re-establishing balance to the ways the body produces and metabolizes fat and by improving control of blood glucose.